Skip to content
Accessibility help

Search NICE…

Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
BNF for Children (BNFC)
Life sciences
More from NICE

Search results

Skip to results

Area of interest

Area of interestAntimicrobial prescribing (40)COVID-19 (34)

Type

TypeGuidance (5088)Indicators (320)News (388)NICE advice (499)Quality standards (259)Research recommendations (1785)

Status

StatusAwaiting development (413)Deferred (3)Discontinued (493)In consultation (26)In development (380)Published (2617)Topic prioritisation (394)

Last updated

Last updatedLast 3 months (232)Last 6 months (375)Last year (637)Last 3 years (1431)

Guidance programme

Guidance programmeAntimicrobial prescribing guidelines (27)Antimicrobial resistance guidance (2)Cancer service guidelines (10)Clinical guidelines (389)COVID-19 rapid guidelines (27)Diagnostics guidance (138)Early value assessment (30)Health technology evaluations (40)HealthTech guidance (848)Highly specialised technologies guidance (49)Interventional procedures guidance (1596)Late stage assessment (8)Medical technologies guidance (207)Medicines practice guidelines (5)NICE guidelines (579)Public health guidelines (89)Safe staffing guidelines (7)Social care guidelines (47)Technology appraisal guidance (2422)

Advice programme

Advice programmeCOVID-19 rapid summaries (8)Evidence summaries (172)Medtech innovation briefings (324)NICE reviews (3)

Showing 2566 to 2580 of 9102 results

Sort by

Crizotinib for treating ALK-positive anaplastic large cell lymphoma or inflammatory myofibroblastic tumour in people 6 to 17 years [TSID10574]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Selumetinib granules for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children 1 to 6 years [TSID12092]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Baricitinib for treating moderate to severe atopic dermatitis in children and young people aged 2 to 17 [TSID10639]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Dupilumab for children with severe atopic dermatitis [TSID10434]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
CT-P43 (ustekinumab biosimilar) for treating moderate to severe plaque psoriasis [TSID11773]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
ABP-654 (ustekinumab biosimilar) for previously treated moderate to severe plaque psoriasis [TSID11790]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Apremilast for treating moderate to severe plaque psoriasis in people aged 6 to 17 [TSID11921]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Secukinumab biosimilar for treating plaque psoriasis [TSID11992]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Guselkumab for treating chronic plaque psoriasis in children aged 6 to 17 years [TSID12002]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Eszopiclone for treating insomnia [TSID12020]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Lebrikizumab for treating atopic dermatitis in children [TSID 12133_TSID 12135]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Lebrikizumab for treating atopic dermatitis in children [TSID12133]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
Risankizumab for treating moderate to severe plaque psoriasis in people 6 to 17 years [TSID12204]
Topic prioritisation
Result type
Technology appraisal guidance
Status
Topic prioritisation
DOASENSE DOAC dipstick product for the detection of direct oral anti-coagulants
Topic prioritisation
Result type
Diagnostics guidance
Status
Topic prioritisation

Previous page
1
…
170
171
Current page 172
173
174
…
607
Page 172 of 607
Next page

Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS) Clinical Knowledge Summaries
British National Formulary (BNF) British National Formulary
BNF for Children (BNFC) British National Formulary for Children
Life sciences
Library and knowledge services

What NICE does
Implementing NICE guidance
Get involved
About us
Careers
News, blogs and podcasts
Newsletters and alerts
Contact us
Leave feedback
Reusing our content
NICE UK Open Content Licence
Syndicate our content
Events

Facebook
X
YouTube
LinkedIn

Accessibility
Freedom of information
Glossary
Terms and conditions
Privacy notice
Cookies

© NICE 2026. All rights reserved. Subject to Notice of rights.